
Please try another search
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company focuses on developing disease modifying treatments for neurodegenerative conditions. The Company's lead product candidate, ATH434, is being used for the treatment of various Parkinson's disease, Dementia with lewy bodies (DLB) as well as various forms of atypical Parkinsonism, such as Multiple System Atrophy (MSA). ATH434, is a set of molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The Company also has a drug discovery platform generating chemical to intercede in disease processes.
Name | Age | Since | Title |
---|---|---|---|
Geoffrey Paul Kempler | 66 | 1997 | Co-Founder & Non-Executive Chairman |
Ira Shoulson | 75 | 2014 | Chairman of Research & Development Advisory Board |
Peter Ashley Marks | 65 | 2005 | Non-Executive Independent Director |
Lawrence B. Gozlan | 42 | 2011 | Non-Executive Director |
Colin Louis Masters | 74 | 1999 | Member of Research & Development Advisory Board |
Brian Derek Meltzer | 67 | 1999 | Non-Executive Independent Director |
Rudolf Emile Tanzi | 63 | 2007 | Chief Scientific Advisor and Member of Research & Development Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review